Leucovorin

Dosage for Leucovorin varies significantly depending on the reason for use and the specific chemotherapy protocol being followed.

Methotrexate Rescue (Post-High Dose Therapy)

The standard protocol usually begins 24 hours after the start of the methotrexate infusion. A common starting dose is 15 mg (approximately 10 mg/m²) every 6 hours for 10 doses. This is continued until the methotrexate blood level falls below a specific threshold (typically 0.05 micromolar). If the patient shows signs of delayed methotrexate elimination (e.g., rising creatinine levels), the dose of Leucovorin may be increased to 100 mg/m² every 3 hours intravenously until the levels are safe.

Advanced Colorectal Cancer (with 5-FU)

There are two primary regimens used in the United States:

1. 1The Mayo Clinic Regimen: Leucovorin 20 mg/m² followed by 5-FU 425 mg/m² intravenously for 5 consecutive days, repeated every 4 to 5 weeks.
2. 2The Roswell Park Regimen: Leucovorin 500 mg/m² as a 2-hour infusion, with 5-FU administered midway through the infusion, repeated once a week for 6 weeks.

Megaloblastic Anemia

For folate deficiency, the typical dose is up to 1 mg per day via intramuscular or intravenous injection. There is no evidence that doses higher than 1 mg/day are more effective.

Leucovorin is frequently used in pediatric oncology, particularly for the treatment of osteosarcoma (bone cancer) as part of high-dose methotrexate protocols. The dosing is generally calculated based on the child's Body Surface Area (BSA) in square meters (m²).

• Rescue Dosing: Similar to adults, 10-15 mg/m² every 6 hours is common.
• Adjustments: Pediatric patients require intensive monitoring of renal function, as children can experience rapid changes in methotrexate clearance.

Renal Impairment

Leucovorin itself is not nephrotoxic (toxic to the kidneys). However, because it is used to rescue patients from methotrexate (which is nephrotoxic), dosage adjustments are critical. If a patient's creatinine clearance drops or their serum creatinine rises by 50% or more, the Leucovorin dose must be increased significantly (often to 100-150 mg every 3 hours) to prevent catastrophic methotrexate toxicity.

Hepatic Impairment

Specific dose adjustments for Leucovorin in patients with liver disease are not well-defined in the manufacturer's labeling. However, since the conversion to the active metabolite occurs partly in the liver, patients with severe hepatic dysfunction should be monitored closely for efficacy.

Elderly Patients

Clinical studies have shown that elderly patients are at a higher risk for severe gastrointestinal toxicity when Leucovorin is combined with 5-fluorouracil. Healthcare providers often start at the lower end of the dosing range and monitor for severe diarrhea and dehydration.

• Oral: Tablets can be taken with or without food. If the dose is higher than 25 mg, your doctor will likely switch you to an injectable form due to the absorption limits of the gut.
• Injection: This must be administered by a healthcare professional in a clinical setting. It should not be administered intrathecally (into the spinal canal), as this can be fatal.
• Storage: Tablets should be stored at room temperature (20°C to 25°C / 68°F to 77°F) in a dry place. Injectable vials should be protected from light.

In the context of chemotherapy rescue, a missed dose is a medical emergency. Leucovorin must be taken exactly on schedule to prevent the methotrexate from killing healthy cells. If you miss a dose at home, call your oncologist or go to the emergency room immediately. For non-cancer uses, take the missed dose as soon as you remember, unless it is almost time for the next dose.

Leucovorin is generally considered to have low toxicity. However, excessive amounts can neutralize the chemotherapeutic effect of methotrexate entirely, potentially allowing the cancer to grow. In combination with 5-FU, an overdose of Leucovorin can lead to severe, life-threatening diarrhea and white blood cell suppression. If an overdose is suspected, contact a Poison Control Center or seek emergency care.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Timing is critical for the success and safety of this medication.

When Leucovorin is used alone at standard doses, side effects are remarkably rare because it is a vitamin derivative. However, when used in combination with chemotherapy, it significantly increases the toxicity of the other drugs.

Common effects when combined with 5-Fluorouracil include:

• Diarrhea: This is often severe and can lead to rapid dehydration. It feels like intense abdominal cramping followed by frequent, watery stools.
• Stomatitis (Mouth Sores): Painful ulcers in the mouth and throat that can make eating or drinking difficult. These usually appear 5-7 days after treatment.
• Nausea and Vomiting: Generally manageable with anti-nausea medications, but can be persistent.
• Leukopenia: A drop in white blood cell counts, which increases the risk of infections. You may feel unusually tired or develop a low-grade fever.

• Anemia: A decrease in red blood cells, leading to shortness of breath and pale skin.
• Thrombocytopenia: A decrease in platelets, which can cause easy bruising or bleeding from the gums.
• Alopecia (Hair Loss): Thinning of the hair or complete loss, though this is primarily driven by the chemotherapy partner drug.
• Skin Rash: Redness, itching, or hives (urticaria).

• Anaphylactoid Reactions: Severe allergic reactions characterized by swelling of the face, difficulty breathing, and a rapid drop in blood pressure.
• Seizures: Reported primarily in patients with existing brain lesions or those taking anticonvulsant medications.
• Insomnia and Agitation: Some patients report feeling 'wired' or unable to sleep after high doses.

> Warning: Stop taking Leucovorin (if oral) and call your doctor immediately or seek emergency care if you experience any of the following:

1. 1Severe Diarrhea: Having more than 4-6 bowel movements over your normal daily amount, or diarrhea that occurs at night.
2. 2Signs of Infection: Fever over 100.4°F (38°C), chills, sore throat, or a cough that won't go away.
3. 3Dehydration: Extreme thirst, dark yellow urine, dizziness when standing up, or dry skin.
4. 4Severe Mouth Sores: Redness, swelling, or sores in the mouth that prevent you from swallowing fluids.
5. 5Allergic Reaction: Swelling of the lips, tongue, or throat; difficulty breathing; or a widespread skin rash.

Because Leucovorin is typically used in cycles or for short durations during chemotherapy rescue, long-term side effects are not well-documented. However, repeated exposure in combination with 5-FU can lead to cumulative 'wear and tear' on the gastrointestinal tract and bone marrow. There is no evidence that Leucovorin causes secondary cancers or long-term organ damage when used as directed.

There are currently no FDA black box warnings for Leucovorin. However, it carries significant 'Precautions' regarding its use with 5-fluorouracil. The labeling emphasizes that Leucovorin increases the toxicity of 5-fluorouracil, and deaths from severe enterocolitis (inflammation of the digestive tract), diarrhea, and dehydration have been reported, particularly in elderly patients.

Report any unusual symptoms to your healthcare provider. Keeping a daily log of your symptoms during chemotherapy can help your medical team adjust your treatment plan to keep you safe.

Leucovorin is a potent biological agent. While it is a form of a B-vitamin, it must be handled with the same caution as the chemotherapy drugs it accompanies. It is not a 'supplement' and should never be used without strict oncological supervision. The most critical safety point is that Leucovorin enhances the toxicity of 5-fluorouracil. While it makes the chemotherapy more effective at killing cancer, it also makes it more effective at damaging the lining of the gut and the bone marrow.

No FDA black box warnings for Leucovorin. However, clinical warnings regarding its use with 5-FU and its potential to mask Vitamin B12 deficiency are considered 'Major Precautions' in the clinical literature.

• Allergic Reactions: Though rare, anaphylaxis can occur. Patients with a known allergy to folic acid or folinic acid should not take this medication.
• Vitamin B12 Deficiency (Pernicious Anemia): This is a critical warning. Leucovorin can improve the blood counts in patients with Vitamin B12 deficiency, making it look like the patient is getting better. However, it does not treat the underlying neurological damage caused by B12 deficiency. If the B12 deficiency remains untreated while the blood counts look normal, the patient can suffer permanent, irreversible nerve damage or blindness.
• Seizure Risk: Leucovorin may increase the frequency of seizures in susceptible individuals, particularly children. It is thought to interfere with the way anti-seizure medications (like phenytoin) work in the brain.
• Gastrointestinal Toxicity: In combination with 5-FU, the risk of severe inflammation of the colon (colitis) is high. This can lead to perforation (holes in the gut) if not managed quickly.

Patients receiving Leucovorin, especially for methotrexate rescue, require intensive monitoring:

1. 1Serum Methotrexate Levels: Blood must be drawn at specific intervals (e.g., 24, 48, and 72 hours) to ensure the drug is leaving the body.
2. 2Serum Creatinine: To check kidney function. If the kidneys slow down, methotrexate levels will spike, requiring more Leucovorin.
3. 3Complete Blood Count (CBC): To monitor white blood cells and platelets.
4. 4Electrolytes: To monitor for dehydration if diarrhea occurs.

Leucovorin itself does not typically cause drowsiness or impaired coordination. However, the conditions it treats (cancer, anemia) and the other drugs it is paired with (5-FU, methotrexate) can cause significant fatigue and dizziness. Patients should assess their reaction to the overall treatment regimen before driving.

Alcohol should be avoided while on Leucovorin therapy. Alcohol can worsen the gastrointestinal side effects (like nausea and diarrhea) and can further strain the liver, which is often already stressed by chemotherapy. Additionally, alcohol interferes with folate metabolism in the body.

In the case of methotrexate rescue, Leucovorin cannot be stopped until methotrexate levels are confirmed to be safe by a lab test. Stopping early can result in fatal toxicity. For other uses, there is no known withdrawal syndrome, but the underlying condition (like anemia) may return if the drug is stopped prematurely.

> Important: Discuss all your medical conditions, especially any history of seizures or anemia, with your healthcare provider before starting Leucovorin.

There are few absolute contraindications for Leucovorin, but it should never be used as the sole treatment for Pernicious Anemia or other megaloblastic anemias where Vitamin B12 deficiency is present. The clinical consequence is the progression of neurological disability while the hematologic (blood) markers appear to recover.

Anticonvulsants (Phenytoin, Phenobarbital, Primidone)

Leucovorin can decrease the blood levels of these anti-seizure medications.

• Mechanism: It is believed that folates increase the metabolism of these drugs in the liver.
• Consequence: Increased risk of breakthrough seizures.
• Management: Doctors should monitor anticonvulsant blood levels closely and adjust the dose as needed when starting or stopping Leucovorin.

5-Fluorouracil (5-FU)

While this is an intentional interaction, it is 'serious' because it significantly increases 5-FU toxicity.

• Mechanism: Leucovorin stabilizes the binding of 5-FU to thymidylate synthase.
• Consequence: Increased risk of severe diarrhea, mouth sores, and low white blood cell counts.
• Management: Careful dose selection and daily monitoring for toxicity.

Trimethoprim and Pyrimethamine

These are 'folic acid antagonists' used for infections (like the antibiotic Bactrim). Leucovorin can interfere with their ability to kill bacteria or parasites, potentially making the infection harder to treat. However, Leucovorin is sometimes used intentionally to reduce the side effects of these drugs in patients with HIV/AIDS.

Fluoropyrimidines (Capecitabine)

Capecitabine (Xeloda) is an oral drug that turns into 5-FU in the body. Taking Leucovorin with it can increase side effects in the same way it does with IV 5-FU.

There are no specific 'forbidden' foods like grapefruit or dairy. However, patients should maintain high fluid intake (2-3 liters per day) to help the kidneys clear the chemotherapy drugs that Leucovorin is rescuing them from. High-fiber foods might worsen diarrhea if it occurs as a side effect.

• Folic Acid Supplements: Taking extra folic acid while on Leucovorin is redundant and could potentially interfere with the precise dosing required for methotrexate rescue.
• St. John's Wort: While not a direct interaction with Leucovorin, it can interact with many chemotherapy drugs and should be avoided.

Leucovorin does not typically interfere with the chemical process of lab tests, but it drastically changes the results of methotrexate level tests (by design) and can mask B12 deficiency in blood smears. It may also cause a false elevation in certain liver function tests if severe diarrhea leads to liver stress.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter vitamins.

1. 1Hypersensitivity: Anyone with a known life-threatening allergic reaction to Leucovorin Calcium or any component of the formulation must not receive the drug. The mechanism is an IgE-mediated immune response that can lead to anaphylaxis.
2. 2Pernicious Anemia / Vitamin B12 Deficiency: As discussed, using Leucovorin for these conditions is absolutely contraindicated because it allows neurological degeneration to continue. The mechanism is that folate can bypass the need for B12 in the DNA synthesis pathway of red blood cells, but it cannot replace B12 in the maintenance of the myelin sheath (the coating of nerves).

1. 1Seizure Disorders: Because Leucovorin can lower the seizure threshold and reduce the effectiveness of anticonvulsants, it must be used with extreme caution in patients with epilepsy.
2. 2Severe Dehydration or Vomiting: In patients who cannot keep fluids down, oral Leucovorin is contraindicated because absorption will be unreliable. These patients must receive the drug intravenously.
3. 3Acidic Pleural Effusions or Ascites: Patients with 'third-space' fluid (fluid in the lungs or abdomen) may see methotrexate leak into these fluids and then slowly leak back out, creating a 'reservoir' of poison. Leucovorin must be used for a much longer duration in these patients.

Patients who are allergic to Levoleucovorin (the 'L' isomer version of the drug, such as Fusilev) will almost certainly be allergic to Leucovorin Calcium, as Leucovorin Calcium contains both the 'L' and 'D' isomers. There is also a potential for cross-sensitivity with other folate-based compounds used in imaging or supplements.

> Important: Your healthcare provider will evaluate your complete medical history, including any history of anemia or neurological issues, before prescribing Leucovorin.

FDA Pregnancy Category C (under the old system). Animal reproduction studies have not been conducted with Leucovorin. It is also not known whether Leucovorin can cause fetal harm when administered to a pregnant woman. However, since Leucovorin is a form of a naturally occurring vitamin (folate), it is generally not thought to be a potent teratogen (substance that causes birth defects). In fact, folates are usually protective. However, because it is almost always used with toxic chemotherapy (methotrexate or 5-FU), the overall treatment regimen is highly dangerous to a fetus. Leucovorin should be used in pregnancy only if clearly needed.

It is not known whether Leucovorin is excreted in human milk. Because many drugs are excreted in milk and because of the potential for serious adverse reactions in nursing infants from the chemotherapy drugs usually given with Leucovorin, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Leucovorin is widely used in children, especially for bone cancer (osteosarcoma). It is considered safe when used according to weight-based or BSA-based protocols. The main concern in children is the risk of increased seizures, particularly in those with CNS tumors or a history of epilepsy. Growth effects have not been specifically linked to Leucovorin, though the underlying cancer and chemotherapy can affect development.

Patients over the age of 65 are at significantly increased risk for severe toxicity when Leucovorin is added to 5-fluorouracil. Clinical data shows that elderly patients experience more severe diarrhea, dehydration, and mouth sores. Physicians often monitor kidney function more frequently in this group, as age-related decline in GFR (Glomerular Filtration Rate) can slow the clearance of the chemotherapy drugs, requiring longer or higher-dose Leucovorin rescue.

While the kidneys do not clear Leucovorin as their only task, they are the primary exit route for methotrexate. If a patient has a GFR below 60 mL/min, they are at high risk for methotrexate toxicity. In these patients, Leucovorin dosing is not 'adjusted down'—rather, it is often 'adjusted up' to provide more protection against the methotrexate that is lingering in the blood.

Patients with severe liver disease (Child-Pugh Class C) may have difficulty converting Leucovorin into its active metabolite, 5-methyltetrahydrofolate. While there are no standard 'dose-reduction' tables for liver disease, doctors may monitor these patients more closely for signs that the 'rescue' isn't working as effectively.

> Important: Special populations require individualized medical assessment and often more frequent lab monitoring.

Leucovorin (folinic acid) is a 5-formyl derivative of tetrahydrofolic acid. Its primary molecular mechanism is to provide a source of reduced folates for purine and pyrimidine synthesis.

1. 1In Methotrexate Rescue: It competes with methotrexate for the same transport carrier into the cell. Once inside, it provides the folate pool necessary for the enzyme thymidylate synthase to continue functioning, even if dihydrofolate reductase is inhibited.
2. 2In 5-FU Potentiation: It is converted to 5,10-methylene tetrahydrofolate, which binds to the complex of 5-FU and thymidylate synthase. This 'ternary complex' is much more stable than the 5-FU/enzyme complex alone, leading to more prolonged inhibition of DNA synthesis in cancer cells.

The effect of Leucovorin is time-dependent and concentration-dependent. In methotrexate rescue, there is a 'threshold' concentration of folate required to overcome the block. If Leucovorin levels fall too low before the methotrexate is gone, DNA synthesis stops abruptly. The onset of effect is rapid (within 30 minutes for IV), and the duration of effect for a single dose is roughly 4 to 6 hours.

| Parameter | Value |

|---|---|

| Bioavailability | 97% (at 25mg dose); 37% (at 100mg dose) |

| Protein Binding | < 15% |

| Half-life | 6.2 hours (total reduced folates) |

| Tmax | 1.7 hours (Oral); 0.7 hours (IM) |

| Metabolism | Rapidly converted to 5-methyltetrahydrofolate |

| Excretion | Renal 80-90%, Fecal 5-8% |

• Molecular Formula: C20H21CaN7O7
• Molecular Weight: 511.5 g/mol (as the calcium salt)
• Solubility: Highly soluble in water (>100 mg/mL).
• Structure: It consists of a pteroic acid nucleus linked to a L-glutamic acid residue, with a formyl group at the 5-position.

Leucovorin is a Folate Analog. It is distinct from folic acid because it is already reduced. Related medications include Levoleucovorin (the pure active isomer) and Pralatrexate (a folate antimetabolite). It is often grouped with 'cytoprotective agents' or 'chemoprotectants' when used for rescue.